MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and BIND Biosciences, Inc. (“COMPANY”), a Delaware corporation, with a principal place of business at 101 Binney Street, Cambridge, MA 02142.
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Delaware
This Amended and Restated License Agreement (this “Agreement”), effective as of 19 April, 2013 (the “Effective Date”), and restated as of June 12, 2013, is made by and between BIND Therapeutics, Inc., a Delaware corporation (“BIND”), and AstraZeneca AB (publ), a company incorporated in Sweden under no 556011-7482 with offices at S-151 85 Södertälje, Sweden (“AstraZeneca”). BIND and AstraZeneca are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
This Amended and Restated License Agreement (this “Agreement”) is effective as of January 7, 2013 (the “Effective Date”), and is restated as of June 10, 2013, by and between BIND Biosciences, Inc., a Delaware corporation (“BIND”), and Amgen Inc., a Delaware corporation (“Amgen”). BIND and Amgen are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
THIS AGREEMENT (the “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and BIND Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located in 64 Sidney Street, Cambridge, Massachusetts 02139 (“LICENSEE”) shall be effective on the date of final execution below (“EFFECTIVE DATE”).
AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY BIND BIOSCIENCES, INC. JHU Ref: # [***]Exclusive License Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Maryland
THIS LICENSE AGREEMENT (the “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”) and BIND Biosciences, Inc., a Delaware corporation (hereinafter the “Company”), having an address at 101 Binney Street, Cambridge, MA 02142, with respect to the following:
